Erasca/$ERAS
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Erasca
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
- Ticker
- $ERAS
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 103
- Headquarters
- San Diego, United States
- Website
- www.erasca.com
Erasca Metrics
BasicAdvanced
$5B
-
-$0.97
0.64
-
Price and volume
Market cap
$5B
Beta
0.64
52-week high
$24.28
52-week low
$2.11
Average daily volume
4.9M
Financial strength
Current ratio
8.294
Quick ratio
8.08
Long term debt to equity
0.109
Total debt to equity
0.124
Profitability
EBITDA (TTM)
-147.743
Management effectiveness
Return on assets (TTM)
-21.39%
Return on equity (TTM)
-78.25%
Valuation
Price to book
12.39
Price to tangible book (TTM)
12.39
Price to free cash flow (TTM)
-16.839
Free cash flow yield (TTM)
-5.94%
Free cash flow per share (TTM)
-0.852
Growth
Earnings per share change (TTM)
114.40%
3-year earnings per share growth (CAGR)
-17.36%
What the Analysts think about Erasca
Analyst ratings (Buy, Hold, Sell) for Erasca stock.
Analyst projections of the future price of Erasca stock.
Bulls say / Bears say
ERAS-0015 produced a 57% eight-week unconfirmed response rate in second-line or later KRAS G12X pancreatic cancer at its recommended dose, an encouraging early signal in a hard-to-treat cancer. The result came from just seven evaluable patients, so it needs confirmation in larger studies. (Erasca)
At the recommended doses, ERAS-0015 showed mostly low-grade side effects, no dose-limiting toxicities or treatment-related discontinuations, and 100% median relative dose intensity. That tolerability could help patients stay on treatment and support combination studies. (Erasca)
Erasca raised $632.5 million in gross proceeds in July, on top of $384.3 million in cash and marketable securities at June-end. The company says this should fund its upcoming milestones, easing near-term financing risk as it advances its trials. (Erasca)
The initial ERAS-0015 data disclosure included a patient death, and analysts said the pneumonitis risk was difficult to judge from the small dataset. This leaves an important safety question unresolved. (Fierce Biotech)
Revolution Medicines alleged that ERAS-0015 infringes its patent and asked Erasca to stop US development, creating legal uncertainty around the company’s lead asset. (Endpoints)
The early response comparisons rely on small Phase 1 cohorts and cross-trial benchmarks, which cannot establish that ERAS-0015 is superior to rival drugs. Short follow-up also leaves the durability of responses uncertain. (Endpoints)
Data summarised monthly by Lightyear AI. Last updated on 16 Oct 2026.
Erasca Financial Performance
Revenues and expenses
Erasca Earnings Performance
Company profitability
Upcoming events
No upcoming events
Erasca News
AllArticlesVideos
ERAS Investors with $100,000 in Losses Have Opportunity to Join Erasca, Inc. Fraud Investigation with SBS Law
Business Wire1 week ago
ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Newsfile Corp2 months ago
ERASCA, INC. (ERAS) SHAREHOLDER INVESTIGATION ALERT: Bernstein Liebhard Investigates Potential Breaches of Fiduciary Duty
Newsfile Corp2 months ago
Funds containing Erasca
Fund name | Fund size | $ERAS weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.33% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.33% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.11% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.11% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | $3.2B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.